Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Titel:
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Auteur:
Beck, Lisa A. Thaçi, Diamant Deleuran, Mette Blauvelt, Andrew Bissonnette, Robert de Bruin-Weller, Marjolein Hide, Michihiro Sher, Lawrence Hussain, Iftikhar Chen, Zhen Khokhar, Faisal A. Beazley, Bethany Ruddy, Marcella Patel, Naimish Graham, Neil M. H. Ardeleanu, Marius Shumel, Brad